Publications 2024

Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW (2024)
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891

Lukina P, Andersen IL, Eggen PT, Mjønes PG, Rønne E, Bolstad N, Klaasen RA, Warren DJ, Iversen R, Hveem K, Bernklev T, Jelsness-Jørgensen LP, Pedersen L, Jonkers I, Lagergren P, Sollid LM, Lundin K, Ness-Jensen E (2024)
Coeliac disease in the Trøndelag Health Study (HUNT), Norway, a population-based cohort of coeliac disease patients
BMJ Open, 14 (1), e077131
DOI 10.1136/bmjopen-2023-077131, PubMed 38195172

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW (2024)
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907

Publications 2023

Bitter H, Warren DJ, Bolstad N, Noraas AL, Ostensen ME (2023)
Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero
Ann Rheum Dis, 82 (4), 577-579
DOI 10.1136/ard-2022-223684, PubMed 36604152

Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323

Jyssum I, Gehin JE, Sexton J, Kristianslund EK, Hu Y, Warren DJ, Kvien TK, Haavardsholm EA, Syversen SW, Bolstad N, Goll GL (2023)
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/kead525, PubMed 37773994

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656

Syversen SW, Gehin JE, Goll GL, Bolstad N, Haavardsholm EA, Lillegraven S (2023)
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Arthritis Rheumatol (in press)
DOI 10.1002/art.42764, PubMed 37984460

Wammer ACP, Nermoen I, Medbøe Thorsby P, Bolstad N, Lima K, Tran H, Følling I (2023)
Insulin autoimmune syndrome: not just one but two different diseases with therapeutic implications
Endocrinol Diabetes Metab Case Rep, 2023 (4)
DOI 10.1530/EDM-23-0032, PubMed 37988766

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW (2023)
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 58 (8), 863-873
DOI 10.1080/00365521.2023.2176252, PubMed 36799155

Publications 2022

Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW (2022)
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981

Dorn-Rasmussen M, Buhl S, Brynskov J, Bay JT, Bolstad N, Klausen TW, Warren DJ, Ainsworth MA, Steenholdt C (2022)
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease
Ther Drug Monit, 44 (2), 290-300
DOI 10.1097/FTD.0000000000000913, PubMed 34387220

Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW (2022)
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
BioDrugs, 36 (6), 731-748
DOI 10.1007/s40259-022-00559-1, PubMed 36315391

Klaasen RA, Warren DJ, Iversen R, Bolstad N, Andersen IL, Mjønes P, Rønne E, Lundin KEA, Sollid LM, Ness-Jensen E (2022)
The development and validation of a high-capacity serological assay for celiac disease
Clin Biochem, 107, 13-18
DOI 10.1016/j.clinbiochem.2022.05.010, PubMed 35660483

Publications 2021

Gehin JE, Klaasen RA, Norli ES, Warren DJ, Syversen SW, Goll GL, Bjøro T, Kvien TK, Mjaavatten MD, Bolstad N (2021)
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Rheumatol Int, 41 (9), 1657-1665
DOI 10.1007/s00296-021-04865-9, PubMed 33944985

Gehin JE, Syversen SW, Warren DJ, Goll GL, Sexton J, Bolstad N, Hammer HB (2021)
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
RMD Open, 7 (3)
DOI 10.1136/rmdopen-2021-001985, PubMed 34911811

Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, Wierød A, Bjøro T, Kvien TK, Bolstad N, Goll GL (2021)
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Scand J Rheumatol, 50 (6), 445-454
DOI 10.1080/03009742.2021.1875040, PubMed 33650469

Grišić AM, Dorn-Rasmussen M, Ungar B, Brynskov J, Ilvemark JFKF, Bolstad N, Warren DJ, Ainsworth MA, Huisinga W, Ben-Horin S, Kloft C, Steenholdt C (2021)
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
United European Gastroenterol J, 9 (1), 91-101
DOI 10.1177/2050640620964619, PubMed 33079627

Syversen SW, Bolstad N, Haavardsholm EA (2021)
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply
JAMA, 326 (11), 1069-1070
DOI 10.1001/jama.2021.11480, PubMed 34546304

Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876

Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077

Publications 2020

Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C (2020)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
Scand J Gastroenterol, 55 (8), 884-890
DOI 10.1080/00365521.2020.1786852, PubMed 32631131

Gjefsen E, Bråten LCH, Goll GL, Wigemyr M, Bolstad N, Valberg M, Schistad EI, Marchand GH, Granviken F, Selmer KK, Froholdt A, Haugen AJ, Dagestad MH, Vetti N, Bakland G, Lie BA, Haavardsholm EA, Nilsen AT, Holmgard TE, Kadar TI, Kvien T, Skouen JS, Grøvle L, Brox JI, Espeland A et al. (2020)
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
BMC Musculoskelet Disord, 21 (1), 698
DOI 10.1186/s12891-020-03720-5, PubMed 33087100

Hager HB, Bolstad N, Warren DJ, Ness MV, Seierstad B, Lindberg M (2020)
Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies
Clin Chem Lab Med, 59 (4), 663-669
DOI 10.1515/cclm-2020-1411, PubMed 33119540

Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ et al. (2020)
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Mitlid-Mork B, Bowe S, Gran JM, Bolstad N, Berg JP, Redman CW, Staff AC, Sugulle M (2020)
Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study
PLoS One, 15 (10), e0240473
DOI 10.1371/journal.pone.0240473, PubMed 33079955

Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, Natvig E, Berstad P, Jørgensen A, Sandvei PK, Olsen ME, Frigstad SO, Darre-Næss O, Norvard ER, Bolstad N, Kørner H, Wibe A, Wensaas KA, de Lange T, Holme Ø (2020)
Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial
Gastroenterology, 160 (4), 1085-1096.e5
DOI 10.1053/j.gastro.2020.11.037, PubMed 33227280

Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385

Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007

Yang M, Lin X, Segers F, Suganthan R, Hildrestrand GA, Rinholm JE, Aas PA, Sousa MML, Holm S, Bolstad N, Warren D, Berge RK, Johansen RF, Yndestad A, Kristiansen E, Klungland A, Luna L, Eide L, Halvorsen B, Aukrust P, Bjørås M (2020)
OXR1A, a Coactivator of PRMT5 Regulating Histone Arginine Methylation
Cell Rep, 30 (12), 4165-4178.e7
DOI 10.1016/j.celrep.2020.02.063, PubMed 32209476

Publications 2019

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML (2019)
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312

Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T (2019)
Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease
JGH Open, 4 (3), 410-416
DOI 10.1002/jgh3.12266, PubMed 32514446

Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E (2019)
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Arthritis Res Ther, 21 (1), 256
DOI 10.1186/s13075-019-2009-5, PubMed 31783773

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G et al. (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722

Publications 2018

Carlsen A, Omdal R, Leitao KØ, Isaksen K, Hetta AK, Karlsen LN, Aabakken L, Bolstad N, Warren D, Lundin KEA, Grimstad T (2018)
Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease
Therap Adv Gastroenterol, 11, 1756284818759930
DOI 10.1177/1756284818759930, PubMed 29623105

Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen I, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML (2018)
Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care
Scand J Rheumatol, 47 (5), 418-421
DOI 10.1080/03009742.2017.1376110, PubMed 29310493

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW (2018)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793

Rieber-Mohn AB, Sugulle M, Wallukat G, Alnæs-Katjavivi P, Leite Størvold G, Bolstad N, Redman CW, Dechend R, Staff AC (2018)
Auto-antibodies against the angiotensin II type I receptor in women with uteroplacental acute atherosis and preeclampsia at delivery and several years postpartum
J Reprod Immunol, 128, 23-29
DOI 10.1016/j.jri.2018.05.008, PubMed 29843114

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE (2018)
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Bone Marrow Transplant, 54 (4), 607-610
DOI 10.1038/s41409-018-0342-y, PubMed 30262906

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N (2018)
Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study
ESC Heart Fail, 5 (6), 1052-1059
DOI 10.1002/ehf2.12312, PubMed 30145817

Publications 2017

Bader LI, Solberg SM, Kaada SH, Bolstad N, Warren DJ, Gavasso S, Gjesdal CG, Vedeler CA (2017)
Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories
Scand J Immunol, 86 (3), 165-170
DOI 10.1111/sji.12572, PubMed 28561325

Hov KR, Bolstad N, Idland AV, Zetterberg H, Blennow K, Chaudhry FA, Frihagen F, Ræder J, Wyller TB, Watne LO (2017)
Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium
Dement Geriatr Cogn Dis Extra, 7 (3), 374-385
DOI 10.1159/000481853, PubMed 29282410

Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Lancet, 389 (10086), 2304-2316
DOI 10.1016/S0140-6736(17)30068-5, PubMed 28502609

Nome RV, Bjøro T, Paus E, Bjerner J, Fosså SD, Steen R, Nustad K, Bolstad N (2017)
Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors
Clin Biochem, 52, 73-79
DOI 10.1016/j.clinbiochem.2017.11.016, PubMed 29198759

Salvador CL, Tøndel C, Rowe AD, Bjerre A, Brun A, Brackman D, Bolstad N, Mørkrid L (2017)
Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase-Associated Lipocalin in Children
J Appl Lab Med, 2 (3), 297-308
DOI 10.1373/jalm.2016.022145, PubMed 33636843

Publications 2016

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Publications 2015

Benterud T, Pankratov L, Solberg R, Bolstad N, Skinningsrud A, Baumbusch L, Sandvik L, Saugstad OD (2015)
Perinatal Asphyxia May Influence the Level of Beta-Amyloid (1-42) in Cerebrospinal Fluid: An Experimental Study on Newborn Pigs
PLoS One, 10 (10), e0140966
DOI 10.1371/journal.pone.0140966, PubMed 26501201

Gislefoss RE, Langseth H, Bolstad N, Nustad K, Mørkrid L (2015)
HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank
Int J Gynecol Cancer, 25 (9), 1608-15
DOI 10.1097/IGC.0000000000000532, PubMed 26501436

Publications 2013

Bolstad N, Warren DJ, Nustad K (2013)
Heterophilic antibody interference in immunometric assays
Best Pract Res Clin Endocrinol Metab, 27 (5), 647-61
DOI 10.1016/j.beem.2013.05.011, PubMed 24094636

Publications 2012

Bjerner J, Bolstad N, Piehler A (2012)
Belief is only half the truth--or why screening for heterophilic antibody interference in certain assays makes double sense
Ann Clin Biochem, 49 (Pt 4), 381-6
DOI 10.1258/acb.2012.011228, PubMed 22740684

Bolstad N, Kazaryan AM, Revheim ME, Distante S, Johnsrud K, Warren DJ, Nustad K, Edwin B (2012)
A man with abdominal pain: enough evidence for surgery?
Clin Chem, 58 (8), 1187-90
DOI 10.1373/clinchem.2011.167015, PubMed 22843812

Bolstad N, Warren DJ, Bjerner J, Kravdal G, Schwettmann L, Olsen KH, Rustad P, Nustad K (2012)
Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera (vol 49, pg 2001, 2011)
Clin. Chem. Lab. Med., 50 (2), 409
DOI 10.1515/cclm-2012-0038

Sachse D, Bolstad N, Jonsson M, Sæves I, Johansson CB, Delezuch W, Hagve M, Hardang IM, Isaksson HS, Ivarsson A, Lehto L, Keikkala E, Mattsson N, Ranta JK, Stavelin A, Sudmann AA, Varsi K (2012)
The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients
Scand J Clin Lab Invest, 72 (5), 374-9
DOI 10.3109/00365513.2012.677544, PubMed 22900743

Publications 2011

Bolstad N, Warren DJ, Bjerner J, Kravdal G, Schwettmann L, Olsen KH, Rustad P, Nustad K (2011)
Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera
Clin Chem Lab Med, 49 (12), 2001-6
DOI 10.1515/CCLM.2011.702, PubMed 21899496

Bolstad N, Øijordsbakken M, Nustad K, Bjerner J (2011)
Human epididymis protein 4 reference limits and natural variation in a Nordic reference population
Tumour Biol, 33 (1), 141-8
DOI 10.1007/s13277-011-0256-4, PubMed 22105734

Publications 2008

Krokeide SZ, Bolstad N, Laerdahl JK, Bjørås M, Luna L (2008)
Expression and purification of NEIL3, a human DNA glycosylase homolog
Protein Expr Purif, 65 (2), 160-4
DOI 10.1016/j.pep.2008.11.014, PubMed 19121397

Publications 2007

Hildrestrand GA, Diep DB, Kunke D, Bolstad N, Bjørås M, Krauss S, Luna L (2007)
The capacity to remove 8-oxoG is enhanced in newborn neural stem/progenitor cells and decreases in juvenile mice and upon cell differentiation
DNA Repair (Amst), 6 (6), 723-32
DOI 10.1016/j.dnarep.2006.12.008, PubMed 17236821